PAPANICOLAOU, DIMITRIS,ROUBENOFF, RONENN,TSENG, BRIAN,GUBSER, CHARLES,GLASS, DAVID
申请号：
TW103127832
公开号：
TW201536318A
申请日:
2014.08.13
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
The disclosure relates to novel regimens for treating sporadic inclusion body myositis and other muscle wasting disorders' which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.本發明係關於用於治療偶發性包涵體肌炎及其他肌肉萎縮病症之新穎方案，該等方案採用治療有效量之肌肉生長抑制素(myostatin)拮抗劑，例如肌肉生長抑制素結合分子，例如肌肉生長抑制素抗體或ActRII受體結合分子、ActRII受體抗體，例如比麥單抗(bimagrumab)抗體。
